EGFR and glioblastoma: The results suggest that for tumors that overexpress specific receptors, such as EGFR as demonstrated in glioblastoma, the antibody-conjugate in NPs can be advantageous in drug delivery and can improve the antiproliferative efficacy in the tumor cells [34].The lack of significant differences in the in vitro cytotoxic effect of both formulations, as shown in Figure 5, can be attributed to the relatively short duration of the assay, which was limited to 24 h.